Turnaround continues with 3% revenue growth at constant exchange rates and EBIT margin improvement
. - Revenue for the first quarter of EUR 138.8 million was up 2.8% at constant exchange rates (CER) and down 1.9% in EU…
. - Revenue for the first quarter of EUR 138.8 million was up 2.8% at constant exchange rates (CER) and down 1.9% in EU…
Immer häufiger werden Mini-Implantate als Alternative zu konventionellen Implantaten zur Verankerung von Totalprothesen…
. - Revenue for Q3 was up 4.8% at constant exchange rates (CER) driving year-to-date revenue up 1.6% at CER to EUR 417.…
. - Revenue for the second quarter was up 2.3% at constant exchange rates (CER) driving revenue for the first half to E…
. - Nobel Biocare will establish the Foundation for Oral Rehabilitation (FOR) as a scholar-led, international initiativ…
. - Continued growth (CER) in North America (+6.8%) and APAC excl. Japan (+8.5%), EMEA down 3.8% with challenges in Ibe…
. - Reported revenue up 5.0% (up 1.5% at CER) to EUR 143.5 million; impacted by natural disasters in Japan - Growth m…
. - World premiere of the new generation NobelReplace implant system - Reinforcing NobelActive product portfolio with…
Year-to-date September 2010: Reported revenue down 0.6% to EUR 423.3 million (CER -5.9%) Sales trend slightly impro…
. - Revenue growth in Q1 at constant exchange rates (CER) minus 9% at EUR 147.0 million - Reported revenue growth minu…